<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Du L</submitter><funding>Innovation Plan for Postgraduates of Jiangsu Province</funding><funding>National Natural Science Foundation of China</funding><funding>Natural Science Foundation of the Jiangsu Higher Education Institutions of China</funding><pagination>e2407462</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12005803</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(15)</volume><pubmed_abstract>Abnormal proliferation of mesangial cells is a hallmark of diabetic nephropathy (DN). However, the cellular signaling mechanisms that regulate this proliferation remain poorly understood. In this study, it is demonstrated that GA-binding protein (GABP), a member of the ETS family of transcription factors composed of GABPα and GABPβ, plays a significant role in the development of renal fibrosis by modulating mesangial cell proliferation. Notably, the deficiency of GABP in mesangial cells inhibits hyperglycemia-induced proliferation and mitigates renal fibrosis in a murine model of type 2 diabetes mellitus (T2DM). RNA sequencing analysis identifies GLI Family Zinc Finger 1 (GLI1) as the principal downstream effector of GABP in diabetic mice, serving as a crucial regulator of the G1/S transition within the cell cycle. Subsequent investigations have demonstrated that GABP interacts with the GLI1 promoter, facilitating mesangial cell proliferation via GLI1-dependent pathways. This is evidenced by the fact that GLI1 knockdown abrogates the proliferation of mesangial cells with GABP overexpression. Consequently, GABP emerges as a pivotal regulator of renal fibrosis and represents a promising therapeutic target for the treatment of diabetic nephropathy.</pubmed_abstract><journal>Advanced science (Weinheim, Baden-Wurttemberg, Germany)</journal><pubmed_title>GABP Promotes Mesangial Cell Proliferation and Renal Fibrosis Through GLI1 in Diabetic Nephropathy.</pubmed_title><pmcid>PMC12005803</pmcid><funding_grant_id>82003822</funding_grant_id><funding_grant_id>81973377</funding_grant_id><funding_grant_id>KYCX19_2252</funding_grant_id><funding_grant_id>20KJB310022</funding_grant_id><funding_grant_id>82073906</funding_grant_id><pubmed_authors>Yin X</pubmed_authors><pubmed_authors>Hu Y</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Lu Y</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Yang Q</pubmed_authors><pubmed_authors>Ren D</pubmed_authors><pubmed_authors>Yang T</pubmed_authors><pubmed_authors>Du L</pubmed_authors><pubmed_authors>Yu X</pubmed_authors><pubmed_authors>Lu Q</pubmed_authors><pubmed_authors>Ming J</pubmed_authors></additional><is_claimable>false</is_claimable><name>GABP Promotes Mesangial Cell Proliferation and Renal Fibrosis Through GLI1 in Diabetic Nephropathy.</name><description>Abnormal proliferation of mesangial cells is a hallmark of diabetic nephropathy (DN). However, the cellular signaling mechanisms that regulate this proliferation remain poorly understood. In this study, it is demonstrated that GA-binding protein (GABP), a member of the ETS family of transcription factors composed of GABPα and GABPβ, plays a significant role in the development of renal fibrosis by modulating mesangial cell proliferation. Notably, the deficiency of GABP in mesangial cells inhibits hyperglycemia-induced proliferation and mitigates renal fibrosis in a murine model of type 2 diabetes mellitus (T2DM). RNA sequencing analysis identifies GLI Family Zinc Finger 1 (GLI1) as the principal downstream effector of GABP in diabetic mice, serving as a crucial regulator of the G1/S transition within the cell cycle. Subsequent investigations have demonstrated that GABP interacts with the GLI1 promoter, facilitating mesangial cell proliferation via GLI1-dependent pathways. This is evidenced by the fact that GLI1 knockdown abrogates the proliferation of mesangial cells with GABP overexpression. Consequently, GABP emerges as a pivotal regulator of renal fibrosis and represents a promising therapeutic target for the treatment of diabetic nephropathy.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Apr</publication><modification>2025-07-03T03:04:32.142Z</modification><creation>2025-07-03T03:04:32.142Z</creation></dates><accession>S-EPMC12005803</accession><cross_references><pubmed>39985381</pubmed><doi>10.1002/advs.202407462</doi></cross_references></HashMap>